Propanc Biopharma, Inc. (PPCB)
| Market Cap | 1.23M -88.5% |
| Revenue (ttm) | n/a |
| Net Income | -23.55M |
| EPS | -85.38 |
| Shares Out | 633.11K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,712 |
| Open | 1.980 |
| Previous Close | 1.920 |
| Day's Range | 1.910 - 1.980 |
| 52-Week Range | 1.630 - 315.000 |
| Beta | 3.34 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the Univers... [Read more]
Financial Performance
Financial StatementsNews
Propanc Biopharma Quarterly report: Q1 2027
Propanc Biopharma has published its Q1 2027 quarterly earnings report on November 13, 2026.
Propanc Biopharma reports preclinical PRP data
Propanc Biopharma (PPCB) announced highlighted new preclinical findings evaluating its pancreatic proenzyme formulation, or PRP, alone and in combination with galunisertib, or GAL, a small-molecule in...
Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer
MELBOURNE, Australia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma targets February start for first-in-human cancer study
Propanc Biopharma (PPCB) announced it is advancing its clinical development program for PRP, its investigational proenzyme-based therapeutic candidate, as preparations continue for its planned Phase 1...
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
"The continued advancement
Propanc Biopharma announces new PRP preclinical data
Propanc Biopharma (PPCB) announced new preclinical data supporting the potential of its lead asset, PRP, to address chemotherapy resistance in pancreatic cancer. In collaborative research led by Maria...
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments
Propanc Biopharma Inc trading halted, news pending
19:50 EDT Propanc Biopharma (PPCB) Inc trading halted, news pending
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, please note that in the third paragraph of the release, the "Reverse Stock Split date...
Propanc Biopharma announces 1-for-10 reverse stock split
Propanc Biopharma (PPCB) announced that its board of directors, approved a 1-for-10 reverse stock split of the company’s issued and outstanding shares of common stock, par value $0.001 per share.
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma announces new preclinical research from PRP programs
Propanc Biopharma (PPCB) announced new preclinical research from an academic-industry collaboration from the Universities of Jaen and Granada, led by Maria Belen Toledo, has identified pancreatic proe...
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
Propanc Biopharma (PPCB) highlighted new preclinical data for its candidate PRP in pancreatic ductal adenocarcinoma and compared that profile with a clinical standard recently established by Revolutio...
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib
MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma files to sell 6.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.5M shares of common stock. The company is not selling any…
Propanc Biopharma Registration statement: Registration filing
Propanc Biopharma filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Propanc Biopharma FY26 EPS ($17.62)
“The Propanc Executive team are delighted with advancements made in the past financial year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “The Company is poised to capitalize on the...
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
"The Company is poised to capitalize on the foundation set
Propanc Biopharma Annual report: Q4 2026
Propanc Biopharma has published its Q4 2026 annual report on September 25, 2026.
Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015
Propanc Biopharma (PPCB) issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca’s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcin...
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Datase...
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...